scholarly journals Low dose penicillamine in systemic sclerosis: is it effective?

2012 ◽  
Vol 3 (3) ◽  
pp. 181-183
Author(s):  
Farah Sameem ◽  
Iffat Hassan ◽  
Imran Majid ◽  
Qazi Masood
Keyword(s):  
Systemic Sclerosis ◽  
Low Dose

scholarly journals AB0621 TOLERABILITY AND SAFETY OF ACETYLSALICYLIC ACID IN PATIENTS WITH SYSTEMIC SCLEROSIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1606.2-1606
Author(s):  
L. Verardi ◽  
E. De Lorenzis ◽  
G. Natalello ◽  
L. Gigante ◽  
U. La Porta ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Adverse Events ◽  
Low Dose ◽  
Disease Duration ◽  
Rank Test ◽  
Digital Ulcers ◽  
Log Rank Test ◽  
Gastrointestinal Intolerance ◽  
Male Sex ◽  
Observation Period

Background:Systemic Sclerosis (SSc) is characterized by an increased incidence of macro- and microvascular complications. Current evidences on efficacy, safety and tolerability of acetylsalicylic acid (ASA) in SSc patients are limited, and the indication to this treatment is based on the experience of each single centre or physician. Esophagus and stomach are the portions of the digestive tract that are more frequently affected by adverse events due to ASA exposure.Objectives:We evaluated the incidence of adverse events associated with low-dose ASA treatment in a cohort of patients affected by SSc.Methods:Demographic data and disease features of 302 patients affected by SSc treated with low-dose ASA were collected and patients were followed-up for a median period of 6.9 years (range: 0-20 years). The proportion of patients taking ASA for secondary prevention for cardiovascular disease was also noted. The incidence of discontinuation of the drug, gastrointestinal intolerance, bleeding and death in the observation period was recorded.Results:Patients had a median age of 54.0 years (19.6-89.4); 91.9% were female, 13.2% were smokers and 44.0% had a BMI≥30Kg/m2. The prevalence of ischemic heart disease, peripheral vascular disease and stroke was of 8.6%, 5.3% and 3.3%, respectively; 48.7% of the patient took ASA in primary cardiovascular prevention. Therapy started after a median disease duration of 4.8 years (range: 0.0- 30.1 years) since the first non-Raynaud symptom and 56.6% of patients had an early disease (less than three years of disease duration). During the observation period, 30 patients (14.3 per 1000 person-years) discontinued ASA after an average period of assumption of 4.6 years (range: 0.3-18.0 years). The main adverse events were heartburn, dyspepsia and hematochezia, recorded in 18 patients (8.6 per 1000 person-years). Eight of them (3.8 per 1000 person-years) had evidence of digestive tract bleeding. Five patients (2.4 per 1000 person-years) discontinued ASA due to recurrent epistaxis. Twenty-eight patients (13.4 per 1000 person-years) died in the follow-up period, 16 of these (7.6 per 1000 person-years) because of SSc-related causes. None of them had evidence of major bleeding. We used Kaplan-Meier analysis to evaluate the incidence of ASA discontinuation. The history of digital ulcers (Log rank test X24.7, p=0.037) and male sex (Log rank test X24.3, p=0.03) were associated with a higher cumulative ASA discontinuation rate due to gastrointestinal intolerance.Conclusion:In our cohort of SSc patients, ASA resulted safe and well tolerated in most cases, despite the risk of gastroesophageal abnormalities due to disease. Although this comforting results, taking in account the lack of controlled-randomized trials about efficacy and safety, the choice to start antiplatelet therapy with ASA should be mandatorily preceded by a careful evaluation of risks and benefits. Furthermore, an attentive monitoring for possible adverse effects is needed during ASA treatment. Patients with digital ulcers and male sex could present less drug tolerability.References:[1]Valentini G et al. Ann Rheum Dis 2019. Beckett VL et al. Arthritis Rheum 1984. Kavian N et al. Vascul Pharmacol 2015. Lavie CJ et al. Curr Probl Cardiol 2017.Disclosure of Interests:Lucrezia Verardi: None declared, Enrico De Lorenzis: None declared, Gerlando Natalello: None declared, Laura Gigante: None declared, Umberto La Porta: None declared, Elisa Gremese Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Sanofi, UCB, Roche, Pfizer, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Sanofi, UCB, Roche, Pfizer, Silvia Laura Bosello Speakers bureau: Abbvie, Pfizer, Boehringer

Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis

2004 ◽  
Vol 50 (5) ◽  
pp. 740-747 ◽  
Author(s):  
Alexander Kreuter ◽  
Frank Breuckmann ◽  
Andrea Uhle ◽  
Norbert Brockmeyer ◽  
Gregor von Kobyletzki ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Low Dose ◽  
Uva1 Phototherapy

Low‐dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease

2006 ◽  
Vol 35 (1) ◽  
pp. 35-38 ◽  
Author(s):  
G. Valentini ◽  
C. Paone ◽  
G. La Montagna ◽  
I. Chiarolanza ◽  
M. Menegozzo ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Low Dose ◽  
Efficacy Study ◽  
Intravenous Cyclophosphamide ◽  
Diffuse Disease

scholarly journals Low-Dose Naltrexone for Pruritus in Systemic Sclerosis

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Tracy Frech ◽  
Kirsten Novak ◽  
Monica P. Revelo ◽  
Maureen Murtaugh ◽  
Boaz Markewitz ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Gastrointestinal Tract ◽  
Los Angeles ◽  
Low Dose ◽  
Treatment Options ◽  
Case Series ◽  
Common Symptom ◽  
Naltrexone Hydrochloride ◽  
The University ◽  
Low Dose Naltrexone

Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT diseases have been successful. In this case series we report three patients that had significant improvement in pruritus and total GIT symptoms as measured by the 10-point faces scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) questionnaire. This small case series suggests LDN may be an effective, highly tolerable, and inexpensive treatment for pruritus and GIT symptoms in SSc.

Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review

2012 ◽  
Vol 31 (9) ◽  
pp. 1395-1400 ◽  
Author(s):  
Li Guo ◽  
Xiao-xiang Chen ◽  
Yue-ying Gu ◽  
He-jian Zou ◽  
Shuang Ye
Keyword(s):  
Systemic Sclerosis ◽  
Literature Review ◽  
Low Dose ◽  
Case Series ◽  
Chinese Patients

Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis

2020 ◽  
Author(s):  
Dijana Perković ◽  
Marin Petrić ◽  
Ivona Božić ◽  
Katarina Borić ◽  
Daniela Marasović Krstulović ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Intravenous Immunoglobulin ◽  
Low Dose

Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases

2012 ◽  
Vol 22 (1) ◽  
pp. 94-99 ◽  
Author(s):  
Zenshiro Tamaki ◽  
Yoshihide Asano ◽  
Masaru Hatano ◽  
Atsushi Yao ◽  
Tomohiko Kawashima ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Imatinib Mesylate ◽  
Preliminary Report ◽  
Low Dose ◽  
Cutaneous Involvement
Sign in / Sign up

Export Citation Format

Share Document